Product Details

Uniprot No.

Q9HCU9

Target Names

BRMS1

Alternative Names

Breast cancer metastasis-suppressor 1, BRMS1

Species Reactivity

Human

Immunogen

A synthesized peptide from human BRMS1 protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

5D3

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.

Form

Liquid

Tested Applications

ELISA, IHC, FC

Recommended Dilution

Application	Recommended Dilution
IHC	1:50-1:200
FC	1:50-1:200

Protocols

ELISA Protocol
Immunohistochemistry (IHC) Protocol
Flow Cytometry (FC) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

BRMS1 (Breast cancer metastasis-suppressor 1) plays a critical role in regulating cancer metastasis by modulating gene expression and signaling pathways that control cell migration and invasion. Originally identified as a suppressor of metastasis in breast cancer models, BRMS1 has since been implicated in the progression of multiple tumor types, making it a valuable target for researchers investigating metastatic mechanisms, tumor suppressor networks, and potential therapeutic strategies.

This recombinant monoclonal antibody, clone 5D3, offers the consistency and reproducibility that demanding research applications require. Generated against a synthetic peptide derived from human BRMS1, the antibody is produced using recombinant technology, ensuring sequence-defined specificity and eliminating the lot-to-lot variability often encountered with traditional hybridoma-derived antibodies. This reliability is particularly valuable for longitudinal studies or multi-site collaborations where experimental consistency is essential.

The antibody has been validated for immunohistochemistry and flow cytometry applications, providing flexibility across different experimental workflows. IHC validation in paraffin-embedded human small intestine tissue demonstrates clear staining at dilutions of 1:50 to 1:200, with antigen retrieval performed using citrate buffer at pH 6.0. Flow cytometry validation using HepG2 cells confirms the antibody's utility for intracellular detection in fixed and permeabilized samples, showing distinct signal separation from isotype control at 1:50 to 1:200 dilutions.

Supplied in a stabilized liquid format with glycerol for long-term storage at -20°C or -80°C, this affinity-purified rabbit IgG antibody is well-suited for researchers studying metastasis suppression, chromatin remodeling complexes, or BRMS1's broader roles in cancer biology and gene regulation.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Target Background

Function

Transcriptional repressor. Down-regulates transcription activation by NF-kappa-B by promoting the deacetylation of RELA at 'Lys-310'. Promotes HDAC1 binding to promoter regions. Down-regulates expression of anti-apoptotic genes that are controlled by NF-kappa-B. Promotes apoptosis in cells that have inadequate adherence to a substrate, a process called anoikis, and may thereby inhibit metastasis. May be a mediator of metastasis suppression in breast carcinoma.

Gene References into Functions

BRMS1FANCI interaction is necessary for the regulatory role of BRMS1 in the FA pathway. PMID: 30365131
overexpression of miR-3200-5p significantly decreased BRMS1 levels and promoted OS cell invasion and migration, while depletion of miR-3200-5p significantly increased BRMS1 levels and inhibited OS cell invasion and migration. Study revealed that miR-3200-5p may be a critical regulator of OS cell invasiveness. PMID: 29890825
Low BRMS1 expression is associated with Hepatocellular carcinoma. PMID: 29295726
Low BRMS1 expression is associated with high metastatic capacity of breast cancer. PMID: 29970691
High BRMS1 Expression is associated with Metastases and recurrence in Lung Adenocarcinoma. PMID: 29097253
The results showed that reduction in the breast cancer metastasis suppressor 1 [BRMS1] expression level was linked directly to clinico-pathological features of breast cancer significantly. The loss of expression or reduced levels of BRMS1 is potentially a strong indicator of the metastatic capacity of breast cancer with poor prognosis. PMID: 28533425
The RAS-related nuclear protein ((P) ran), breast cancer metastasis suppressor 1 ((P) brms1) and minichromosome maintenance complex component 5 ((P) mcm5) promoters have the specificity and strength needed for cancer-specific expression-targeted gene therapy. PMID: 27140445
we identify a therapeutically exploitable posttranslational mechanism by which CK2alpha-mediated degradation of BRMS1 promotes metastases in lung cancer PMID: 26980766
our study characterized DAPK1 as a novel transcriptional target of BRMS1. Transcriptional activation of DAPK1 might be another important mechanism accounting for the metastasis suppressive activity of BRMS1. PMID: 28339067
BRMS1 promoter methylation and aberrant protein expression seem to be related to high-risk types of human papilloma virus-induced carcinogenesis in uterine cervix. PMID: 28381193
miR-346 promotes migration and invasion of nasopharyngeal carcinoma cells via targeting BRMS1. PMID: 27501413
A novel link has been discussed between CDK2 expression and cell migration by characterizing the CDK2-mediated phosphorylation of BRMS1. PMID: 26730572
Phosphorylation of BRMS1 by CDK2 regulates the migration of tumor cells. PMID: 26771717
Data show that Cullin3 exerts its function through promoting breast-cancer metastasis suppressor 1 (BRMS1) protein degradation, which was associated with epithelial-mesenchymal transition (EMT), migration and invasion. PMID: 26544623
The studies reviewed here with respect to BRMS1 structure, cellular effects, intracellular signaling, and clinical value consolidate the importance of BRMS1 in the development of metastasis. PMID: 26328523
Aberrant methylation of BRMS1 frequently occurs in the down-regulation of BRMS1 in triple negative breast cancer and that it may play a role in the metastasis of breast cancer. PMID: 26617826
the present study demonstrates a mechanical cascade of BRMS1 suppressing cancer cell invasion through downregulating HIF-1alpha transcript and consequently reducing Snail and TWIST1 expression. PMID: 26520789
MRTF-A and STAT3 synergistically recruited DNMT1 to hypermethylate the promoter of BRMS1 and affect the expression of BRMS1.MRTF-A and STAT3 promote breast cancer cell migration via hypermethylating BRSM1. PMID: 25854163
BRMS1 expression in human breast cancer is negatively correlated with JARID1C expression. Our results, for the first time, portray a pivotal role of JARID1C in regulating metastatic behaviors of breast cancer cells PMID: 26182878
high expression of BRSM1 in rectal cancer plays an essential role in tumor progression PMID: 24748145
loss of BRMS1 promotes malignant phenotypes that are dependent on NF-kappaB-dependent regulation of Twist1 PMID: 25368381
BRMS1 is a key regulator required to maintain a cellular morphology and cytoskeletal architecture consistent with an epithelial phenotype. PMID: 24763730
BRMS1 overexpression inhibited glioma cell invasion. PMID: 24879377
BRMS1-expressing cells remained rounded. PMID: 24000122
Silencing of BRMS 1 significantly induced the expression of NF-kappaB subunit, p65, uPA, and OPN proteins PMID: 24984534
Methylation of BRMS1 promoter in cfDNA isolated from plasma of NSCLC patients provides important prognostic information and merits to be further evaluated as a circulating tumour biomarker. PMID: 24642624
Data define BRMS1 promoter methylation in primary breast tumors and associated circulating tumor cells. PMID: 23744981
Low levels of BRMS1 were observed in patients with high-grade tumors, in patients with distant metastasis in breast cancer. PMID: 24596389
BRMS1 SNP rs1052566 heterozygous individuals were more likely to have node-positive breast tumors. PMID: 23771732
Report BRMS1 transcript variant which regulates heptocellular carcinoma apoptosis and growth. PMID: 23643861
Authors observed that residues 85 to 98 might be important in defining the oligomerization state of the BRMS1 N-terminal coiled coil. PMID: 23500495
The C-terminal putative nuclear localization sequence (NSL2) of BRMS1 is necessary for metastasis suppression. PMID: 23390556
Data suggest that low expression of the metastasis suppressor BRMS1 may be an independent prognostic factor for poor prognosis in nasopharyngeal carcinoma (NPC) patients. PMID: 22931099
The expression of BRMS1 protein in supraglottic cancer is significantly decreased. BRMS1 gene promotor methylation is related with down-expression of BRMS1 protein. PMID: 23167184
Data indicate that mutation of E3 ligase motif not only abolishes BRMS1-induced p300 polyubiquitination and degradation, but importantly, dramatically reduces the metastasis suppressor function of BRMS1. PMID: 23269275
BRMS1 sensitizes HCC cells to apoptosis through suppressing OPN expression PMID: 22927944
The loss of BRMS1 expression may be involved in the development and progression of nasal and paranasal sinus carcinomas. PMID: 22239051
Loss of breast cancer metastasis suppressor 1 promotes ovarian cancer cell metastasis by increasing chemokine receptor 4 expression. PMID: 22200669
high level of expression and lack of promoter methylation are associated with better overall survival in non-small cell lung cancer patients PMID: 21726917
These results suggest that the novel regulatory mechanism of BRMS1 by Cul3-SPOP complex is important for breast cancer progression. PMID: 22085717
SATB1 and BRMS1 might play an important role in the development and lymph node metastasis of ovarian cancer. PMID: 21355308
possible link between BRMS1 expression and apoptosis in human breast cancer through a relationship with the expression of genes belonging to the X-chromosome RBM family. PMID: 21737612
the enigmatic complexities of BRMS1-mediated metastasis suppression PMID: 21827753
The expression of BRMS1 protein in supraglottic cancer is significantly decreased. Expression has a close relationship with pathologic differentiation and clinical stage and cervical lymph node metastasis. PMID: 19621595
Expression of BRMS1 mRNA in supraglottic cancer is lower than that in adjacent normal mucosa. PMID: 18533556
BRMS1 expression was decreased in metastatic melanomas, which resulted in deficient suppression of angiogenesis and contributed to melanoma progression. PMID: 20935672
Study observed that SNX6 increases BRMS1-dependent transcriptional repression. Moreover, over-expression of SNX6 was capable of diminishing trans-activation in a dose-dependent manner. PMID: 20830743
Patients with high levels of expression of BRMS1 mRNA have a better prognosis than those with low expression. PMID: 17085653
ING4 is induced by BRMS1 and that it inhibits melanoma angiogenesis by suppressing NF-kappaB activity and IL-6 expression. PMID: 21056991
BRMS1 expression in breast cancer cells induced reorganization of F-actin and caused alteration in cytoarchitectures (cell topography and ultrastructure). PMID: 20083343

Hide All

Subcellular Location

Nucleus. Cytoplasm. Note=Predominantly nuclear.

Protein Families

BRMS1 family

Tissue Specificity

Expression levels are higher in term placentas than in early placentas. Low levels of expression observed in normal pregnancies and in molar pregnancies.

Database Links

HGNC: 17262

OMIM: 606259

KEGG: hsa:25855

STRING: 9606.ENSP00000396052

UniGene: Hs.100426

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA986010A0HU
Size	US$210
	Order now
Image	IHC image of CSB-RA986010A0HU diluted at 1:100 and staining in paraffin-embedded human small intestine tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB. Overlay Peak curve showing HepG2 cells stained with CSB-RA986010A0HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for 10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/110⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 35min at 4℃.Control antibody (green line) was Rabbit IgG (1ug/110⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.
Have Questions?	Leave a Message or Start an on-line Chat

BRMS1 Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background